MA31768B1 - Formulations galeniques de composes organiques - Google Patents

Formulations galeniques de composes organiques

Info

Publication number
MA31768B1
MA31768B1 MA32758A MA32758A MA31768B1 MA 31768 B1 MA31768 B1 MA 31768B1 MA 32758 A MA32758 A MA 32758A MA 32758 A MA32758 A MA 32758A MA 31768 B1 MA31768 B1 MA 31768B1
Authority
MA
Morocco
Prior art keywords
organic compounds
dosage formulations
dosage form
oral dosage
relates
Prior art date
Application number
MA32758A
Other languages
Arabic (ar)
English (en)
Inventor
Jean-Claude Bianchi
Heiko Busies
Andreas Meyer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40377181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31768(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31768B1 publication Critical patent/MA31768B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention porte sur une forme posologique orale solide compactée au rouleau comprenant une quantité thérapeutiquement efficace d'aliskirène, ou d'un sel pharmaceutiquement acceptable de celui-ci, l'ingrédient actif étant présent dans une quantité de plus de 38 % en poids sur la base du poids total de la forme posologique orale. L'invention porte également sur un procédé de préparation de ladite forme posologique orale solide.
MA32758A 2007-09-28 2010-04-08 Formulations galeniques de composes organiques MA31768B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97589407P 2007-09-28 2007-09-28
PCT/EP2008/062769 WO2009040373A2 (fr) 2007-09-28 2008-09-24 Formulations galéniques de composés organiques

Publications (1)

Publication Number Publication Date
MA31768B1 true MA31768B1 (fr) 2010-10-01

Family

ID=40377181

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32758A MA31768B1 (fr) 2007-09-28 2010-04-08 Formulations galeniques de composes organiques

Country Status (22)

Country Link
US (1) US20110033533A1 (fr)
EP (2) EP2548553A1 (fr)
JP (1) JP5378384B2 (fr)
KR (1) KR20100076996A (fr)
CN (1) CN101808630A (fr)
AR (1) AR068539A1 (fr)
AU (1) AU2008303504C1 (fr)
BR (1) BRPI0817586A2 (fr)
CA (1) CA2697229A1 (fr)
CL (1) CL2008002828A1 (fr)
CO (1) CO6270216A2 (fr)
GT (1) GT201000064A (fr)
MA (1) MA31768B1 (fr)
MX (1) MX2010003260A (fr)
MY (1) MY148266A (fr)
NZ (1) NZ584005A (fr)
PE (1) PE20091203A1 (fr)
RU (1) RU2483718C2 (fr)
TN (1) TN2010000120A1 (fr)
TW (1) TWI436760B (fr)
WO (1) WO2009040373A2 (fr)
ZA (1) ZA201001144B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009143423A1 (fr) * 2008-05-23 2009-11-26 Teva Pharmaceutical Industries Ltd. Monofumarate d’aliskirène et procédés de préparation associés
WO2011116115A1 (fr) 2010-03-16 2011-09-22 Novartis Ag Composition d'aliskiren comprenant un acide gras à chaîne moyenne et procédé de fabrication correspondant
TR201002256A1 (tr) 2010-03-24 2011-10-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Stabil aliskiren formülasyonları
US20110268797A1 (en) 2010-04-30 2011-11-03 Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi Multicoated aliskiren formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US6521647B2 (en) * 2000-04-04 2003-02-18 Pfizer Inc. Treatment of renal disorders
WO2002043807A2 (fr) * 2000-12-01 2002-06-06 Novartis Ag Combinaison de composants organiques
RU2183116C1 (ru) * 2001-07-10 2002-06-10 Жаров Олег Владимирович Фармацевтическая композиция, обладающая болеутоляющим, противовоспалительным, антипиретическим и спазмолитическим действием
WO2004100871A2 (fr) * 2003-05-09 2004-11-25 Pharmacia Corporation Combinaison d'un antagoniste du recepteur de l'aldosterone et d'un inhibiteur de renine
AR048431A1 (es) * 2004-03-17 2006-04-26 Novartis Ag Formulaciones galenicas de compuestos organicos
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2006116435A2 (fr) * 2005-04-27 2006-11-02 Novartis Ag Methodes de traitement de l'atherosclerose
WO2007056324A2 (fr) * 2005-11-08 2007-05-18 Novartis Ag Combinaison de composes organiques pour le traitement des maladies cardiovasculaires
TW200804241A (en) * 2006-02-24 2008-01-16 Novartis Ag New salt
GB0605688D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic compounds
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (fr) * 2006-08-25 2008-02-27 Novartis AG Formulations galéniques de l'aliskiren
US20100130616A1 (en) * 2006-11-09 2010-05-27 Novartis Ag Salt of aliskiren with orotic acid
EP1972335A1 (fr) * 2007-03-23 2008-09-24 Krka Formes de dosage solide comportant de l'aliskiren et ses sels pharmaceutiques acceptables
AU2008309058B2 (en) * 2007-09-28 2012-08-09 Novartis Ag Galenical formulations of Aliskiren and Valsartan

Also Published As

Publication number Publication date
TN2010000120A1 (en) 2011-09-26
RU2010116530A (ru) 2011-11-10
CL2008002828A1 (es) 2009-05-15
TW200922546A (en) 2009-06-01
AU2008303504C1 (en) 2013-05-16
NZ584005A (en) 2012-08-31
MY148266A (en) 2013-03-29
AU2008303504B2 (en) 2012-03-22
CA2697229A1 (fr) 2009-04-02
WO2009040373A2 (fr) 2009-04-02
PE20091203A1 (es) 2009-09-11
JP5378384B2 (ja) 2013-12-25
CN101808630A (zh) 2010-08-18
US20110033533A1 (en) 2011-02-10
AU2008303504A1 (en) 2009-04-02
ZA201001144B (en) 2011-12-28
RU2483718C2 (ru) 2013-06-10
EP2205232A2 (fr) 2010-07-14
EP2548553A1 (fr) 2013-01-23
KR20100076996A (ko) 2010-07-06
TWI436760B (zh) 2014-05-11
JP2010540489A (ja) 2010-12-24
BRPI0817586A2 (pt) 2015-03-31
AR068539A1 (es) 2009-11-18
WO2009040373A3 (fr) 2009-08-20
CO6270216A2 (es) 2011-04-20
MX2010003260A (es) 2010-04-29
GT201000064A (es) 2012-03-30

Similar Documents

Publication Publication Date Title
MY144477A (en) Galenic formulations of organic compounds
WO2010068810A3 (fr) Amides substitués, et leurs procédés de production et d'utilisation
NZ584686A (en) Compositions of trisodium [3-((1S,3R)-1-biphenyl-4-ylmethyl-3-ethoxycarbonyl-1-butylcarbamoyl) propionate(S)-3'-methyl-2' -(pentanoyl{ 2 -(tetrazol-5-ylate)biphenyl-4'-ylmethyl} amino)butyrate]hemipentahydrate
BRPI0517438A (pt) composto, método para tratar a condição associada com atividade de receptor muscarìnico m4, uso do composto, e, composição farmacêutica
GEP20084527B (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
NZ593782A (en) Compositions for drug administration comprising a triptan analog and an alkylsaccharide
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
WO2006009789A3 (fr) Derives piperazine a substitution aryle
MA32787B1 (fr) Peptides antiviraux therapeutiques
MA31768B1 (fr) Formulations galeniques de composes organiques
MY151295A (en) Pyrimidyl indoline compound
MA32964B1 (fr) Formulation a effet retard d'octreotide avec niveau d'exposition constamment eleves
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
WO2007125398A3 (fr) Sulfonamides
FR2910317B1 (fr) Forme galenique pour l'administration par voie transmuqueuse de paracetamol
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
MY140410A (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
MA33166B1 (fr) Utilisation de dérivés de pyrimidylaminobenzamide pour le traitement de la fibrose
TW200621223A (en) Acyclic 1,3-diamines and uses therefor
MA33619B1 (fr) Agent thérapeutique pour des troubles de l'anxiété
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
PE20060743A1 (es) Formulaciones inyectables o administrables por via oral de derivados de azetidina
WO2008065144A3 (fr) Préparations galéniques de composés organiques
WO2007027987A3 (fr) Methode de traitement de la maladie de parkinson par des composes de diarylmethylpiperazine a activite agoniste du recepteur delta